Storia: Q&A: Akeso CEO spells out why she thinks its biliary tract cancer data are a big deal

WARPTECHNEWS · LAB

Chinese biotech firm Akeso Inc has announced positive interim results from a registrational Phase-3 trial, showing that its home-grown bispecific antibody ivonescimab combined…

Q&A: Akeso CEO spells out why she thinks its biliary tract cancer data are a big deal

Confronto fonti

Q&A: Akeso CEO spells out why she thinks its biliary tract cancer data are a big deal

Timeline cronologica

Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary…

Chinese cancer treatment shows survival edge in trial

Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate

Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus…

China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial

Chinese cancer treatment shows survival edge in trial

Akeso, Summit hail ivonescimab's biliary tract cancer win in China-only Phase 3 trial

Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate

China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial

Q&A: Akeso CEO spells out why she thinks its biliary tract cancer data are a big deal